New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2013
07:05 EDTATHXAthersys announces EMA issued positive opinion for MultiStem therapy
Athersys announced that the Committee for Orphan Medicinal Products of the European Medicines Agency, or EMA, has issued a positive opinion for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem therapy, for the prevention of graft-versus-host disease, or GvHD. The Company is developing its MultiStem cell therapy as a GvHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell, or HSC, transplant and is currently preparing for a Phase II/III clinical study in the area. The MultiStem therapy for the prevention of GvHD has also previously been granted orphan drug designation by the FDA.
News For ATHX From The Last 14 Days
Check below for free stories on ATHX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ATHX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use